Cost per responder analysis of iptacopan versus eculizumab and ravulizumab in treatment of paroxysmal nocturnal hemoglobinuria

That is the tile of my recent paper in the Journal of Medical Economics with co-authors Kyi-Sin Than, Sanjana Muthukrishnan, Jincy Paulose, Ver Bilano and Nicholas Kuypers. The abstract is below: ObjectiveParoxysmal nocturnal hemoglobinuria (PNH) is a rare and debilitating hematological disease with significant economic burden. Despite the availability of multiple therapies, there is a…

Read More

How AI Enables Unified Patient Journeys for Faster, More Accurate Rare Disease Diagnoses

Every year shaved off the diagnostic odyssey means fewer irreversible complications, fewer misdiagnoses, and fewer clinicians and families left wondering what they missed. A unified, longitudinal approach doesn’t just speed up diagnosis — it changes, and in some cases saves, lives. The post How AI Enables Unified Patient Journeys for Faster, More Accurate Rare Disease…

Read More

Friday AI Links

ChatGPT introduces OpenAI for Healthcare.AI can make prescription renewals in Utah.AMA’s perspective of physicians role with AI.US Army’s use of AI to improve soldiers’ mental health.Claim the AI skill boost.

Read More